GIANG NGUYEN: Open Payments
NPI 1982097929 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$793 in 30 payments from 9 companies in 2025. Trend: 2023 $396 · 2024 $604 · 2025 $793
Food & beverage: $793
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $354 |
| AstraZeneca Pharmaceuticals LP | 4 | $164 |
| Phathom Pharmaceuticals, Inc. | 1 | $112 |
| ABBVIE INC. | 4 | $68 |
| Dexcom, Inc. | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Amgen Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| PFIZER INC. | 1 | $15 |
Products named: VOQUEZNA, AIRSUPRA, Rybelsus, Ozempic, QULIPTA, BREZTRI, FARXIGA, Dexcom G6 Transmitter.
Industry payments across TX — which companies pay providers there.
